With the BD Veritor™ Plus System you're

"All set!"



Enable more efficient diagnosis and care for respiratory illnesses with reliable tests for COVID-19 & Flu A+B†, COVID-19‡, Flu A+B, Group A Strep and RSV.

In seasons of high demand, lean on clear, rapid results in 15 minutes or less to streamline appointments and get your urgent care patients back to what matters most.*

Elevate patient experiences with rapid answers from the portable, simple-to-use BD Veritor™ Plus System.

Ready, set, go to **bdveritor.com**

BD

BD Veritor™ Plus System

Avoid delays in diagnosis of critical respiratory illnesses

Optimize workflows and elevate patient experiences. Point-of-care respiratory testing from the BD Veritor™ Plus System delivers rapid and reliable results on a single compact instrument to help enable more efficient care and treatment.

Expeditious and comprehensive

Prioritize turnaround times by quickly identifying common respiratory illnesses.

Enhanced efficiency

Streamline appointments for patients with reliable results at the point-of-care.

Confident, quality care

Count on reliable respiratory testing products, backed by a trusted partner in BD.

Contact your authorized distributor partner or BD to learn more.
For expedited service, say **Veritor** at the prompt. **1.844.823.5433**

*Result processing times for each BD Veritor™ assay are 15 minutes for the SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays, 10 minutes for Flu A+B and RSV assays, and 5 minutes for the Group A Strep assay.

†**For SARS-CoV-2:** In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

‡**For SARS-CoV-2 & FLU A+B:** In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152, U.S.
1.800.638.8663

bd.com